+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

A pharma CEO just jacked up the price of a 62-year-old drug by $736 a pill, and he's responding to critics on Twitter with Eminem quotes

Sep 22, 2015, 01:40 IST

Advertisement
Bloomberg TV screenshot

Martin Shkreli, the hedge-fund-manager-turned-pharmaceutical-CEO, is in hot water after raising the price of the anti-parasite medication Daraprim from $13.50 a pill to $750.Turing, which Shkreli founded in February, bought the US marketing rights to the drug in August. Shkreli told Bloomberg TV he hiked up the prices because his company "need[ed] to turn a profit on the drug."It's common practice for drug companies to set the prices for their new products. What puts Turing in the spotlight is that this is a vastly different price on a drug that's been around for six decades.The New York Times reported the news on Sunday, bringing up criticism to the choice to raise the drug's price.Shortly afterwards, Shkreli tweeted out a line of Eminem lyrics:andApart from the edgy Eminem lyrics, Shkreli's other tweets are pretty fantastic, like this killer humblebrag. And this amazing puppy pic.Here's some more rap-related tweeting. Despite his most recent emotion-fueled defensive tweets, the CEO occasionally gets serious. But it also looks like he has some good ideas about the direction pharmaceuticals should go, as far as transparency and new treatments are concerned.For example, right after Turing acquired the US marketing rights to Daraprim, Shkreli tweeted about the importance of developing drugs to treat neglected tropical diseases. He also discussed his business strategy for rewarding scientists who develop new treatments for Turing. Shkreli said he will give the scientists a royalty, or payment based on how much of the drug is sold. His tweet claims very few pharmaceutical companies do this. He then elaborated on what that might look like. Thanks for the tweets, Shkreli. 

NOW WATCH: More trouble for Subway's Jared Fogle...

Please enable Javascript to watch this video
You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article